It is a pleasure to report that the Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is up 35% in the last quarter. But in truth the last year hasn't been good for the share price. After all, the share price is down 18% in the last year, significantly under-performing the market.
With the stock having lost 11% in the past week, it's worth taking a look at business performance and seeing if there's any red flags.
Check out our latest analysis for Rhythm Pharmaceuticals
Because Rhythm Pharmaceuticals made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
In the last year Rhythm Pharmaceuticals saw its revenue grow by 226%. That's a strong result which is better than most other loss making companies. Given the revenue growth, the share price drop of 18% seems quite harsh. Our sympathies to shareholders who are now underwater. On the bright side, if this company is moving profits in the right direction, top-line growth like that could be an opportunity.
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
If you are thinking of buying or selling Rhythm Pharmaceuticals stock, you should check out this FREE detailed report on its balance sheet.
A Different Perspective
Investors in Rhythm Pharmaceuticals had a tough year, with a total loss of 18%, against a market gain of about 12%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 2% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 3 warning signs for Rhythm Pharmaceuticals you should know about.
Of course Rhythm Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of growth stocks.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.